Kyung Nam Pharm Early Redeems 2.5 Billion Won 8th Convertible Bond, Preventing Potential Dilution and Enhancing Financial Stability
On June 22, 2026, Kyung Nam Pharm acquired the entire 2.5 billion won face value of its 8th unsecured private convertible bond for 2.51 billion won using its own funds and cancelled the bonds, following the bondholder's exercise of early redemption rights.
The bonds were issued in September 2023 with an initial conversion price of 3,165 won per share, subsequently adjusted due to a stock consolidation. This acquisition eliminates potential dilution of approximately 790,000 shares upon conversion, protecting existing shareholder value.
The debt repayment using internal funds reduces financial leverage and interest burdens, though the significant cash outflow may pressure short-term liquidity. Investors should monitor subsequent cash flow changes.
[AI Summary]Kyung Nam Pharm's early redemption of the 2.5 billion won convertible bond removes dilution overhang and improves its debt ratio, positively impacting stock price stability. However, the large cash outlay reduces financial flexibility and warrants vigilance on future funding plans.
KOSDAQ Filing Information
Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) Before Maturity After Issuance